35 CHF CHF 35.00
AG-CN2-0455-M01010 mgCHF 35.00
AG-CN2-0455-M05050 mgCHF 80.00
AG-CN2-0455-M250250 mgCHF 240.00
|Merck Index||14: 7048|
|Source/Host Chemicals||Isolated from Magnolia grandiflora.|
|Purity Chemicals||≥98% (HPLC)|
|Appearance||White to light green solid.|
|Solubility||Soluble in DMSO, ethanol or dichloromethane. Insoluble in water.|
|Identity||Determined by 1H-NMR.|
|Shipping and Handling|
|Short Term Storage||+20°C|
|Long Term Storage||+4°C|
|Handling Advice||Protect from light.|
|Use/Stability||Stable for at least 2 years after receipt when stored at +4°C.|
|Product Specification Sheet|
- Anticancer and antiangiogenic compound. Induces apoptosis, cell cycle arrest and autophagy in various cancer cell lines.
- At low concentrations acts as antioxidant reducing oxidative stress generated through the TCR signaling pathway. At high concentration induces O2- and causes oxidative-stress-mediated apoptosis.
- Potent anti-inflammatory and anti-atherosclerotic agent.
- NF-κB inhibitor by directly targeting IκB kinase.
- Inhibits STAT-mediated anti-apoptotic gene transcription.
- NLRP3 inflammasome inhibitor. Inhibits ATPase activity of NLRP3 and protease activity of caspase 1.
- Directly binds the pattern recognition receptor NOD2.
- Specifically inhibits HDAC1 without affecting other class I/II HDACs.
- DNA methyltransferase 1 (DNMT1) inhibitor.
- Induces ubiquitination of MDM2 resulting in the activation of p53 and other MDM2-regulated tumor suppressor proteins.
- VEGF inhibitor. Reduces the expression of VEGF and its receptors VEGRF1 and 2.
- Inhibits tubulin carboxypeptidase (TCP) activity.
- Microtubule-interfering compound, inhibiting cell migration and tubule formation.
- Anti-leishmanial and anti-trypanosomal agent.
- Partial TRPA1 agonist.
- Tumor inhibitory agent from Magnolia grandiflora (Magnoliaceae). I. Parthenolide: R.M. Wiedhopf, et al.; J. Pharm. Sci. 62, 345 (1973)
- The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase: B.H. Kwok, et al.; Chem. Biol. 8, 759 (2001)
- Cell cycle effects and caspase-dependent and independent death of HL-60 and Jurkat cells treated with the inhibitor of NF-kappaB parthenolide: P. Pozarowski, et al.; Cell Cycle 2, 377 (2003)
- Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium: T.S. Tiuman, et al.; Antimicrob. Agents Chemother. 49, 176 (2005)
- Dual role of the anti-inflammatory sesquiterpene lactone: regulation of life and death by parthenolide: M. Li-Weber, et al.; Cell Death Differ. 12, 408 (2005)
- Parthenolide inhibits tubulin carboxypeptidase activity: X. Fonrose, et al.; Cancer Res. 67, 3371 (2007)
- Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated: Y.N. Gopal, et al.; Chem. Biol. 14, 813 (2007)
- Trypanosoma cruzi: antiprotozoal activity of parthenolide obtained from Tanacetum parthenium (L.) Schultz Bip. (Asteraceae, Compositae) against epimastigote and amastigote forms: E. Izumi, et al.; Exp. Parasitol. 118, 324 (2008)
- Modulation of DNA methylation by a sesquiterpene lactone parthenolide: Z. Liu, et al.; J. Pharmacol. Exp. Ther. 329, 505 (2009)
- Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions: Y.N. Gopal, et al.; Mol. Cancer Ther. 8, 552 (2009)
- Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome: C. Juliana, et al.; J. Biol. Chem. 285, 9792 (2010)
- Inhibition of pattern recognition receptor-mediated inflammation by bioactive phytochemicals: L. Zhao, et al.; Nutr. Rev. 69, 310 (2011) (Review)
- Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities: V.B. Mathema, et al.; Inflammation 35, 560 (2012) (Review)
- Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel: S. Materazzi, et al.; Pain 154, 2750 (2013)
- Parthenolide exerts inhibitory effects on angiogenesis through the downregulation of VEGF/VEGFRs in colorectal cancer: S.L. Kim, et al.; Int. J. Mol. Med. 33, 1261 (2014)
- Parthenolide-induced apoptosis, autophagy and suppression of proliferation in HepG2 cells: J. Sun, et al.; Asian Pac. J. Cancer Prev. 15, 4897 (2014)